| Name | Title | Contact Details |
|---|---|---|
Spencer Clark |
SVP and General Counsel | Profile |
Roxanne Womack |
SVP, Chief Compliance Officer | Profile |
Spencer Clark |
VP and Senior Legal Counsel | Profile |
Kelly Whelan |
VP and Senior Legal Counsel, American and Eastern Groups | Profile |
Spire’s Remote Patient Monitoring service pairs revolutionary respiratory sensing technology with licensed medical staff to identify changes in patient health and intervene earlier.
The Franciscan Alliance healthcare ministry began in Lafayette` Ind.` in 1875. Today` Franciscan Alliance is one of the largest Catholic health care systems in the Midwest with 14 hospital campuses in Indiana and Illinois` approximately 20`000 employees and a number of nationally recognized Centers of Health Care Excellence. Hospitals include: Franciscan Health Crown Point; Franciscan Health Michigan City; Franciscan Health Crawfordsville; Franciscan Health Lafayette East; Franciscan Health Lafayette Central; Franciscan Health Indianapolis; Franciscan Health Carmel; Franciscan Health Rensselaer; Franciscan Health Mooresville; Franciscan Health Chicago Heights` Ill.; Franciscan Health-Olympia Fields` Ill.; Franciscan Health Hammond; Franciscan Health Dyer; and Franciscan Health Munster. For more information` visit FranciscanHealth.org. With more than 850 primary and specialty care providers at over 260 locations in Indiana and Illinois` Franciscan Physician Network is one of the largest and most respected multi-specialty physician networks in the Midwest providing convenient` comprehensive care.
Visiting Nurse Service is a Northport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Radiancy, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Orangeburg, NY. To find more information about Radiancy, Inc., please visit www.radiancy.com